Boehringer Ingelheim Corporation Backs Transparency But Calls for IP Protection  
8/8/2013 7:11:53 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Charles de Wet, Boehringer Ingelheim’s medical director for the UK and Ireland, says the company is wholeheartedly committed to data transparency but does not favour the approach being adopted by the AllTrials campaign. The aforementioned initiative believes that all trials past and present should be registered, and the full methods and the results reported. The AllTrials campaign, set up by groups such as Sense About Science, Bad Science, the BMJ and the Cochrane Collaboration, has the backing of a number of healthcare associations but only one drugmaker to date, GlaxoSmithKline.

Help employers find you! Check out all the jobs and post your resume.